Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: DynaGen

This article was originally published in The Tan Sheet

Executive Summary

DynaGen: Bristol-Myers Squibb has decided not to exercise its right of first refusal to license DynaGen's NicErase-SL lobeline-based smoking cessation product ("The Tan Sheet" May 15, p. 7). DynaGen announced July 13 that Bristol-Myers Squibb will not pursue development of Bristol-Myers, NicErase as a prescription smoking cessation product because the company's "strategic interest is in over-the-counter products." DynaGen, which recently completed a pilot Phase III study with NicErase ("The Tan Sheet" July 3, In Brief), said it will accelerate discussions with other interested parties...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel